$CME

SHEPARD WILLIAM R purchased $3K of CME

SHEPARD WILLIAM R purchased 14 shares of CME GROUP INC. (CME) at $230.57 on 2026-06-25.

Original reporting
SEC EDGAR · SHEPARD WILLIAM R
Published Jun 29, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CME
Neutral
high confidence
Mentioned
$CME
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMENeutralLow
01

Why it matters

The newest fact is the director’s open-market purchase details (14 shares at $230.57) and post-transaction holdings (3,621 shares).

02

Market read

Traders may note the insider buy, but the transaction is small and does not introduce new operational or financial information.

03

What to watch

No 10b5-1 plan is stated, but the filing lacks context on intent, timing constraints, or whether this is part of a broader pattern.

Relevance 4/10Novelty 3/10Timing: after-hours/filing timestamp 2026-06-29; reflects 2026-06-25 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for CME Group Inc.

Company-level read

Ticker impact

$CMENeutralHigh confidence
Context

SEC Form 4 shows director SHEPARD WILLIAM R bought 14 shares of CME at $230.57 on 2026-06-25, totaling $3,301.30.

Expected impact

Likely minimal near-term impact; any effect is sentiment-only and small.

Evidence & confidence

The filing is a small, non-material insider buy (14 shares) with no 10b5-1 plan and no accompanying company news.

Market effects

None; this is company-specific insider transaction with no sector datapoint.

None indicated.

None indicated.

Counterpoint

A director purchase can be interpreted as confidence, but the disclosed size is too small to meaningfully change valuation expectations.

Key entities

  • CME Group Inc.

    Subject of the Form 4 insider transaction disclosure.

  • SHEPARD WILLIAM R

    Director who reported the open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CMEMed

FanDuel Gets FCM License, Raising Questions Over CME Role in Predicts

FanDuel has received a futures commission merchant (FCM) license from the National Futures Association, allowing it more control over its U.S. prediction market business. The approval raises questions about its partnership with CME Group, which holds a 51% stake in FanDuel Predicts. CME's CEO previously stated that such a license could conflict with their agreement. FanDuel's new license does not permit it to operate its own exchange, but it may seek further approvals in the future.

$CMEMed

Baseball may get its first stats-based trading contracts Oct. 12, pending regulatory review.

CME Group plans to launch baseball futures on October 12, 2026, pending regulatory approval. The contracts will track CME FutureSports Performance Indexes, based on official league data of 30 professional baseball teams. Standard contracts will be valued at 10x the indexes, while micro contracts will be 1/10 their value. Trading will begin with the 2026 Postseason and the four clubs in the League Championship Series.

$FLUTHigh

FanDuel Lands FCM License, But CME Isn’t Involved

FanDuel, owned by Flutter Entertainment (FLUT), secured a futures commission merchant (FCM) license from the National Futures Association. This approval may alter FanDuel's relationship with CME Group (CME), the majority owner of FanDuel Predicts. FanDuel has been expanding its prediction market operations, including a partnership with Crypto.com. CME has expressed concerns about FanDuel's potential competitive threat.